Conference Proceedings

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies

Gavin Cull, Stephen Opat, Judith Trotman, James Hilger, Xiaoping Zhang, Shibao Feng, Sunhee Ro, Jane Huang, Constantine S Tam

BLOOD | AMER SOC HEMATOLOGY | Published : 2017


Funding Acknowledgements

Amgen Australia: Other: travel expenses Lugano lymphoma conference 2017; Takeda Australia: Other: travel expenses Highlights of ASH march 2017, Brisbane. Opat: Janssen: Consultancy, Honoraria, Speakers Bureau; Gilead: Consultancy, Honoraria, Research Funding, Speakers Bureau; Roche: Consultancy, Honoraria, Research Funding, Speakers Bureau; Beigene: Research Funding; Mundipharma: Consultancy; Amgen: Research Funding. Trotman: Janssen Cilag: Other: Funding facilitating research paid to third party (BioGrid Australia), Research Funding. Hilger: BeiGene: Employment. Zhang: BeiGene: Employment. Feng: BeiGene: Employment. Ro: BeiGene: Employment. Huang: BeiGene: Employment. Tam: Abbvie: Honoraria, Research Funding; Janssen Cilag: Honoraria, Research Funding; Roche: Honoraria, Research Funding.